Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
VY-3-135
Cat. No.:
OB0225LY-0009
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by HPLC.
Size:
Product Overview
Description:
VY-3-135 is an stable acetyl-CoA synthetase 2 (ACSS2) inhibitor that effectively inhibits ACSS2-dependent fatty acid metabolism.
Synonym:
1824637-41-3; (R)-1-Ethyl-2-(hydroxydiphenylmethyl)-N-(2-hydroxypropyl)-1H-benzo[d]imidazole-6-carboxamide; 3-Ethyl-2-[hydroxy(diphenyl)methyl]-N-[(2R)-2-hydroxypropyl]benzimidazole-5-carboxamide
CAS No.:
1824637-41-3
Compound CID:
92131155
Formula:
C26H27N3O3
Formula Weight:
429.51
Specification
Relative Density:
1.21 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
VY-3-135 can be used as an ACSS2 inhibitor to study fatty acid metabolism and breast cancer development.
Library Information
Targets:
Lipid metabolism; Fatty acid synthesis
Receptors:
ACSS2
Pathways:
Metabolism
Plate Number:
AOCL-1
Plate Location:
a10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 116.41 mM
